Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?

Figures

• 

  Figure 1. Possible integration of the four new classes of drugs (ARNI, gliflozins, vericiguat, and omecamtiv mecarbil) with the other medications (beta-blockers, ivabradine, ACEi, angiotensin-converting enzyme inhibitor, ARBs, angiotensin receptor blockers, MRA, mineral corticoid receptor antagonist), according to different phenotypes (CHF with: low blood pressure, hyperkalemia, CKD, increased arrhythmic burden) of CHF patients. Preferred, Possible, Not suggested or great caution needed.

• 

  Figure 2. Possible integration of the four new classes of drugs (ARNI, gliflozins, vericiguat, and omecamtiv mecarbil) with the other medications (beta-blockers, ivabradine, ACEi, angiotensin-converting enzyme inhibitor, ARBs, angiotensin receptor blockers, MRA, mineral corticoid receptor antagonist), according to different phenotypes (CHF in sinus rhythm with: HR ≥ 70 beat/min, CHF with AF and HR > 100 or < 100 beats/min) of CHF patients. Preferred, Possible, Not suggested or great caution needed.

• 

  Figure 3. Possible combination of the four new classes of drugs (ARNI, gliflozins, vericiguat, and omecamtiv mecarbil) with the other medications (beta-blockers, ivabradine, ACEi, angiotensin-converting enzyme inhibitor, ARBs, angiotensin receptor blockers, MRA, mineral corticoid receptor antagonist), according to different phenotypes of post-acute HFrEF patients. Preferred, Possible, Not suggested or great caution needed.